Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction
2009 (English)In: British Journal of Clinical Pharmacology, ISSN 0306-5251, E-ISSN 1365-2125, Vol. 68, no 3, 427-34 p.Article in journal (Refereed) Published
AIMS: In a systematic screening of the World Health Organization Adverse Drug Reaction database, VigiBase, in July 2008, a measure of association used to detect interactions (Omega) highlighted azithromycin with the individual statins atorvastatin, lovastatin and simvastatin and rhabdomyolysis. The aim was to examine all reports including rhabdomyolysis-azithromycin and statins in VigiBase to assess if the data were suggestive of an interaction.
METHODS: The individual case reports in VigiBase and the original files were reviewed. In order to investigate the reporting over time for rhabdomyolysis with azithromycin and statins to VigiBase, Omega values were generated retrospectively.
RESULTS: The reporting over time showed that rhabdomyolysis under concomitant use of azithromycin and statins was reported more often than expected from 2000 and onwards in Vigibase. After exclusion of possible duplicates and follow-up reports, 53 cases from five countries remained. Rhabdomyolysis occurred shortly after initiation of azithromycin in 23% of cases. In 11 patients an interaction had been suggested by the reporter. With the exception of one patient, the statin doses reported were within the recommended daily doses.
CONCLUSIONS: Case reports in VigiBase are suggestive that interactions between azithromycin and statins resulting in rhabdomyolysis may occur. This analysis showed the potential of the newly developed disproportionality measure, Omega, which can help to identify drug interactions in VigiBase in the future. The results also showed that reviewing spontaneous reports can add information to drug interactions not established previously.
Place, publisher, year, edition, pages
Wiley-Blackwell, 2009. Vol. 68, no 3, 427-34 p.
Adverse drug reaction reporting systems, azithromycin, disproportionality measure, drug interaction, statins, WHO-ADR database
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-70846DOI: 10.1111/j.1365-2125.2009.03473.xISI: 000269575200015PubMedID: 19740401OAI: oai:DiVA.org:liu-70846DiVA: diva2:442057